TRIFERIC AVNU
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIFERIC AVNU (TRIFERIC AVNU).
Triferic AVNU (ferric pyrophosphate citrate) is an iron replacement product that provides iron to hemoglobin synthesis without increasing circulating iron levels. It is taken up by transferrin and delivered to erythroid precursor cells for heme synthesis.
| Metabolism | Ferric pyrophosphate citrate is metabolized to release iron, which is incorporated into hemoglobin. The metabolic fate of the pyrophosphate and citrate components is not fully characterized. |
| Excretion | Renal excretion of iron is minimal (<5% of administered dose); most iron is incorporated into hemoglobin or stored as ferritin/hemosiderin. Biliary/fecal excretion is negligible. |
| Half-life | Terminal half-life of ferric pyrophosphate citrate is approximately 6-8 hours in patients with iron deficiency. In patients with normal iron stores, half-life may be longer due to redistribution. The iron component is not eliminated but conserved. |
| Protein binding | Transferrin: iron binds to transferrin (approximately 99.9% bound) for transport. Ferritin and hemosiderin intracellular storage. |
| Volume of Distribution | Vd: approximately 0.3 L/kg for the iron complex; iron distributes primarily to bone marrow, liver, and spleen. Central volume is constrained by transferrin binding. |
| Bioavailability | Intravenous: 100% bioavailability. Not administered orally. |
| Onset of Action | Intravenous: Reticulocyte response within 3-7 days; hemoglobin increase detectable within 1-2 weeks. |
| Duration of Action | Duration of effect on hemoglobin lasts weeks to months depending on severity of deficiency and ongoing losses. Iron stores are replenished over weeks. |
| Molecular Weight | 433.3 Da (as ferric carboxymaltose complex, molecular weight variable) |
Triferic Avnu (ferric pyrophosphate citrate) is administered intravenously at a dose of 2 mg iron per liter of dialysate fluid, delivered during each hemodialysis session via the dialysate line.
| Dosage form | SOLUTION |
| Renal impairment | Triferic Avnu is specifically indicated for use in hemodialysis patients. No dose adjustment is required based on GFR as it is administered during dialysis and the drug is not dependent on renal clearance. |
| Liver impairment | No specific hepatic dose adjustments are provided in the label. Use with caution in patients with severe hepatic impairment due to lack of data. |
| Pediatric use | The safety and efficacy of Triferic Avnu in pediatric patients have not been established. No dosing recommendations are available. |
| Geriatric use | No specific dose adjustments are recommended for geriatric patients. Clinical studies included patients aged 65 and older, and no overall differences in safety or efficacy were observed. |
| 1st trimester | Data limited; avoid unless clearly needed. Iron overdose can cause fetal harm. |
| 2nd trimester | Use if benefits outweigh risks; monitor iron levels. |
| 3rd trimester | Can cause iron overload in fetus; avoid high doses. |
Clinical note
Comprehensive clinical and safety monograph for TRIFERIC AVNU (TRIFERIC AVNU).
| Placental transfer | Iron crosses placenta; degree depends on formulation and maternal iron status. |
| Breastfeeding | Iron is excreted in breast milk but unlikely to harm infant. Use caution with high doses; may cause GI upset in infant. |
| Lactation Rating | L2 (Probably Compatible) |
■ FDA Black Box Warning
No black box warning
| Serious Effects |
Hypersensitivity to iron productsAnemia not due to iron deficiencyIron overload (e.g., hemochromatosis)Hereditary fructose intolerance (if contains sucrose)
| Precautions | Hypersensitivity reactions including anaphylaxis have been reported., Iron overload can occur; monitor iron status (serum ferritin, transferrin saturation) regularly., Contains aluminum; avoid in patients with aluminum overload or toxicity risk. |
| Food/Dietary | No specific food interactions with Triferic Avnu as it is administered intravenously via dialysate. However, patients should follow a renal diet as advised by their nephrologist (e.g., limit phosphorus, potassium, sodium). Oral iron supplements should not be taken concurrently unless directed. |
Loading safety data…
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Iron deficiency anemia treatment is beneficial, but ferric carboxymaltose is FDA pregnancy category B. Animal studies show no teratogenicity. Risk of fetal hypoxia from maternal anemia outweighs potential risks. |
| Fetal Monitoring | Monitor hemoglobin, hematocrit, reticulocyte count, and iron parameters (serum ferritin, transferrin saturation). Assess for symptoms of hypersensitivity reactions. Monitor fetal growth and well-being if severe maternal anemia. |
| Fertility Effects | No known adverse effects on fertility. Correcting iron deficiency may improve fertility outcomes related to anovulation or menstrual irregularities associated with iron deficiency. |
| Clinical Pearls | Triferic Avnu (ferric pyrophosphate citrate) is administered via dialysate during hemodialysis to replace iron lost during the procedure and maintain hemoglobin levels without increasing IV iron or ESA doses. Monitor transferrin saturation (TSAT) and ferritin monthly; target TSAT 30-50%. Do not use for acute iron repletion in iron deficiency anemia. Not interchangeable with other iron products. |
| Patient Advice | This medication is given through your dialysis fluid to replace iron lost during dialysis. · It helps maintain your red blood cell levels without needing extra iron shots or ESA medications. · You will have regular blood tests to check your iron levels. · Do not take additional oral iron supplements unless prescribed by your doctor. · Report any signs of allergic reaction such as rash, itching, or difficulty breathing during dialysis. |